



(51) International Patent Classification:

C07K 14/005 (2006.01) C12N 7/00 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2017/030375

(22) International Filing Date:

01 May 2017 (01.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/330,604 02 May 2016 (02.05.2016) US

(71) Applicant: THE SCRIPPS RESEARCH INSTITUTE
[US/US]; 10550 North Torrey Pines Road, La Jolla, CA
92037 (US).(72) Inventors: KONG, Leopold; 4920 Battery Lane, #3,
Bethesda, MD 20814 (US). WILSON, Ian, A.; 1025
Newkirk Drive, La Jolla, CA 92037 (US). DE VAL, Na-
talia; 4860 Clairemont Mesa Blvd., #4, San Diego, CA
92117 (US). WARD, Andrew, B.; 4965 Academy Street,San Diego, CA 92109 (US). BURTON, Dennis; 6044
Beaumont Avenue, La Jolla, CA 92037 (US). HE, Lin-
ling; 4267 Robins Street, San Diego, CA 92122 (US). ZHU,
Jiang; 4267 Robins Street, San Diego, CA 92122 (US).(74) Agent: FITTING, Thomas et al.; The Scripps Research In-
stitute, 10550 North Torrey Pines Road, TPC-8, La Jolla,
CA 92037 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS




FIG. 1

(57) Abstract: The present invention provides HiV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N- terminus of the HRI region in gp41. Some of the immunogens contain an HIV-1 Env- derived trimer protein that is presented on 8 nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*